A Phase 3 interventional study of liraglutide in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 47 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-09-05.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 8 that started in 2015, is one of 45 in phase 3, and was the 107th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 635 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 66th largest by enrollment of the 428 interventional ones that give a count, is one of 17 that started in 2015, is one of 187 in phase 3, and was the 401st registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 635 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
Drug: liraglutide
The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
Drug: liraglutide
Injected subcutaneously s.c. (under the skin) once daily.
Change in Glycosylated Haemoglobin (HbA1c) (Week 26)
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of treatment. The change from baseline in the response after 26 weeks of treatment is analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline response as a covariate.
Time frame: Week 0, Week 26
Change in HbA1c (Week 52)
Change from baseline (week 0) in HbA1c was evaluated after 52 weeks of treatment.
Time frame: Week 0, Week 52
Responder for HbA1c Below 7.0% (53 mmol/Mol)
Reported results are number of subjects who achieved HbA1c target below 7.0% after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Responder for HbA1c Below or Equal to 6.5% (48 mmol/Mol)
Reported results are number of subjects who achieved HbA1c target below or equal to 6.5% after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Responder for HbA1c Below 7.0% Without Weight Gain
Reported results are number of subjects who achieved HbA1c target below 7.0% without weight gain after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Responder for HbA1c Below 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
Reported results are subjects with HbA1c \<7.0% after 26 weeks and 52 weeks of treatment, respectively without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes. Severe or BG confirmed symptomatic hypoglycaemia: severe as per ADA classification or BG confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA: episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk)0) and no later than 7 days after the last day on liraglutide (maximum till wk26+7days and wk52+7days). Hence, the following shown 'Time Frame' should be read as 'Wk26+7days and Wk52+7days'
Time frame: Week 26 and Week 52
Change in Self-Measured Blood Glucose (SMBG) 7-point Profile: 7-point Profile (Individual Points in the Profile)
Reported results are 7-point SMBG values at week 0, week 26 and week 52. The 7-point profile blood glucose levels were measured at the following time points always starting with the first: 1. Before breakfast. 2. 90 minutes after start of breakfast. 3. Before lunch. 4. 90 minutes after start of lunch. 5. Before dinner. 6. 90 minutes after start of dinner. 7. At bedtime.
Time frame: Week 0 and Week 26 and Week 52
Change in SMBG 7-point Profile: Mean of 7-point Profile
Change from baseline (week 0) in mean of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in SMBG 7-point Profile: Mean of Postprandial Increments (From Before Meal to 90 Minutes After for Breakfast, Lunch and Dinner)
Change from baseline (week 0) in mean of postprandial increments (from before meal to 90 minutes after for breakfast, lunch and dinner) of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Fasting Plasma Glucose (FPG)
Change from baseline (week 0) in FPG was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Waist Circumference
Change from baseline (week 0) in waist circumference was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Body Weight
Change from baseline (week 0) in body weight was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Body Mass Index (BMI)
Change from baseline (week 0) in BMI was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Blood Pressure (Systolic and Diastolic)
Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Fasting C-peptide
Fasting C-peptide was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Fasting Insulin
Fasting insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Fasting Glucagon
Fasting glucagon was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Proinsulin
Proinsulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Proinsulin/Insulin
Proinsulin/insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Homeostasis Model Assessment of Beta-cell Function (HOMA-B)
HOMA-B was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-B is an index of beta-cell function and was calculated as: HOMA-B=\[(20 x fasting insulin in µU/mL)/(FPG in mmol/L-3.5)\].
Time frame: Week 26 and Week 52
Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)
HOMA-IR was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-IR is an index of insulin resistance and was calculated as: HOMA-IR= fasting insulin (μU/mL) x FPG (mmol/L)/22.5.
Time frame: Week 26 and Week 52
Total Cholesterol
Total cholesterol was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Low Density Lipoprotein (LDL) Cholesterol
LDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
High Density Lipoprotein (HDL) Cholesterol
HDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Very Low Density Lipoprotein (VLDL) Cholesterol
VLDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Triglycerides
Triglycerides were evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Free Fatty Acids
Free fatty acids were evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 26 and Week 52
Number of Treatment Emergent Adverse Events
Treatment emergent adverse events (TEAEs) were evaluated during the 26-week and 52-week treatment period, respectively. TEAE for weeks 0-26: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 26 + 7 days). TEAE for weeks 0-52: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 52 + 7 days). Hence, the following shown 'Time Frame' should be read as 'Weeks 0-26 + 7 days and Weeks 0-52 + 7 days'.
Time frame: Weeks 0-26 and Weeks 0-52
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the 26-week and 52-week treatment period, respectively. Severe or BG confirmed symptomatic hypoglycaemia (hypo):An episode that was severe according to the ADA classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypo. ADA definition of severe hypo:episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk) 0) and no later than 7 days after the last day on liraglutide (maximum till wk 26 and wk 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'wk 0-26+7 days and wk 0-52+7 days'.
Time frame: Weeks 0-26 and Weeks 0-52
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Treatment emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the26-week and 52-week treatment period, respectively. Nocturnal hypoglycaemic episodes: Those occurring between 00:01 and 05:59 hours, both inclusive. Severe or BG confirmed symptomatic hypoglycaemia: episode that was severe according to the ADA classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Treatment emergent: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.
Time frame: Weeks 0-26 and Weeks 0-52
Number of Treatment Emergent Hypoglycaemic Episodes According to ADA Definition
American Diabetes Association (ADA) classification of hypoglycaemia: 1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2. Documented symptomatic: PG level ≤3.9 mmol/L with symptoms. 3. Asymptomatic: PG level ≤3.9 mmol/L without symptoms. 4. Probable symptomatic: No measurement with symptoms. 5. Pseudo: PG level \>3.9 mmol/L with symptoms. Treatment emergent hypoglycaemic episode: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.
Time frame: Weeks 0-26 and Weeks 0-52
Change in Pulse
Change from baseline (week 0) in pulse was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Physical Examination
Reported results are physical examination outcomes at week (wk) 0, wk 26 and wk 52. Physical examination consisted of the following listed examinations and the outcome of each examination was evaluated as: 1) normal, 2) abnormal, not clinically significant (NCS) or 3) abnormal, clinically significant (CS). 1. Cardiovascular system 2. Central and peripheral nervous system (PNS) 3. Gastrointestinal (GI) system including mouth 4. General appearance 5. Head, ears, eyes, nose, throat, neck 6. Lymph node palpation 7. Musculoskeletal system 8. Respiratory system 9. Skin 10. Thyroid gland
Time frame: Week 0 and Week 26 and Week 52
Change in Eye Examination
Reported results are eye examination (ophthalmoscopy) outcomes at week 0, week 26 and week 52. Ophthalmoscopy outcomes for both left and right eye were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.
Time frame: Week 0 and Week 26 and Week 52
Change in Electrocardiogram (ECG)
Reported results are ECG outcomes at week 0, week 26 and week 52. ECG outcomes were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.
Time frame: Week 0 and Week 26 and Week 52
Change in Biochemistry: Creatinine
Change from baseline (week 0) in creatinine was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: eGFR
Change from baseline (week 0) in estimated glomerular filtration rate (eGFR) was evaluated after 26 weeks and 52 weeks of treatment, respectively. eGFR was evaluated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, mL/min/1.73m\^2.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Alanine Aminotransferase
Change from baseline (week 0) in alanine aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Aspartate Aminotransferase
Change from baseline (week 0) in aspartate aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Alkaline Phosphatase
Change from baseline (week 0) in alkaline phosphatase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Sodium
Change from baseline (week 0) in sodium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Potassium
Change from baseline (week 0) in potassium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Albumin
Change from baseline (week 0) in albumin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Total Bilirubin
Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Urea
Change from baseline (week 0) in urea was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Creatine Kinase
Change from baseline (week 0) in creatine kinase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Calcium
Change from baseline (week 0) in calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Albumin Corrected Calcium
Change from baseline (week 0) in albumin corrected calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Amylase
Change from baseline (week 0) in amylase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Biochemistry: Lipase
Change from baseline (week 0) in lipase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Haematology: Haemoglobin
Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26, Week 52
Change in Haematology: Haematocrit
Change from baseline (week 0) in haematocrit was evaluated after 26 weeks and 52 weeks of treatment, respectively. Haematocrit is the ratio of the volume of red blood cells to the total volume of blood.
Time frame: Week 0, Week 26, Week 52
Change in Haematology: Thrombocytes
Change from baseline (week 0) in thrombocytes (platelets) was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26 and Week 52
Change in Haematology: Erythrocytes
Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26 and Week 52
Change in Haematology: Leukocytes
Change from baseline (week 0) in leukocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26 and Week 52
Change in Haematology: Eosinophils
Change from baseline (week 0) in eosinophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26 and Week 52
Change in Haematology: Neutrophils
Change from baseline (week 0) in neutrophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26 and Week 52
Change in Haematology: Basophils
Change from baseline (week 0) in basophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26 and Week 52
Change in Haematology: Monocytes
Change from baseline (week 0) in monocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26 and Week 52
Change in Haematology: Lymphocytes
Change from baseline (week 0) in lymphocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Time frame: Week 0, Week 26 and Week 52
Change in Calcitonin
Reported results are number of subjects with low, normal or high calcitonin values at week 0, week 26 and week 52. Number of subjects analyzed = number of subjects contributed to the analysis for individual time point. Calcitonin values were categorised as low, normal or high.
Time frame: Week 0 and Week 26 and Week 52
The trial was conducted at 47 sites in Japan: 47 sites screened and 45 of them randomised subjects. After screening, 635 subjects entered into the 12-week run-in period.
| Milestone | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Started | 233 | 233 |
| Completed | 218 | 194 |
| Not completed | 15 | 39 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Lack of efficacy | 7 | 17 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 8 |
| Withdrew: Unclassified | 4 | 10 |
| Milestone | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Started | 212 | 0 |
| Completed | 194 | 0 |
| Not completed | 18 | 0 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Lack of efficacy | 4 | 0 |
| Withdrew: Withdrawal by subject | 6 | 0 |
| Withdrew: Unclassified | 3 | 0 |
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of treatment. The change from baseline in the response after 26 weeks of treatment is analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline response as a covariate.
| Percentage (%) of HbA1c | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) (Week 26) | -0.23 ± 0.06 | 0.17 ± 0.06 |
Change from baseline (week 0) in HbA1c was evaluated after 52 weeks of treatment.
| Percentage (%) of HbA1c | Liraglutide 1.8 mg |
|---|---|
| Week 0: Baseline | 8.14 ± 1.02 |
| Week 52: Change from baseline | -0.09 ± 1.05 |
Reported results are number of subjects who achieved HbA1c target below 7.0% after 26 weeks and 52 weeks of treatment, respectively.
| Participants | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 53 | 18 |
| Week 52 | 45 | — |
Reported results are number of subjects who achieved HbA1c target below or equal to 6.5% after 26 weeks and 52 weeks of treatment, respectively.
| Participants | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 18 | 5 |
| Week 52 | 16 | — |
Reported results are number of subjects who achieved HbA1c target below 7.0% without weight gain after 26 weeks and 52 weeks of treatment, respectively.
| Participants | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 36 | 13 |
| Week 52 | 35 | — |
Reported results are subjects with HbA1c \<7.0% after 26 weeks and 52 weeks of treatment, respectively without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes. Severe or BG confirmed symptomatic hypoglycaemia: severe as per ADA classification or BG confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA: episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk)0) and no later than 7 days after the last day on liraglutide (maximum till wk26+7days and wk52+7days). Hence, the following shown 'Time Frame' should be read as 'Wk26+7days and Wk52+7days'
| Participants | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 53 | 18 |
| Week 52 | 45 | — |
Reported results are 7-point SMBG values at week 0, week 26 and week 52. The 7-point profile blood glucose levels were measured at the following time points always starting with the first: 1. Before breakfast. 2. 90 minutes after start of breakfast. 3. Before lunch. 4. 90 minutes after start of lunch. 5. Before dinner. 6. 90 minutes after start of dinner. 7. At bedtime.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Before breakfast | 181.8 ± 42.8 | 177.1 ± 43.4 |
| Week 0: 90 minutes after start of breakfast | 262.6 ± 65.0 | 266.5 ± 70.0 |
| Week 0: Before lunch | 169.5 ± 57.7 | 177.6 ± 61.7 |
| Week 0: 90 minutes after start of lunch | 253.1 ± 64.5 | 252.2 ± 63.5 |
| Week 0: Before dinner | 173.4 ± 59.2 | 169.7 ± 56.5 |
| Week 0: 90 minutes after start of dinner | 254.3 ± 66.2 | 249.5 ± 63.2 |
| Week 0: At bedtime | 226.1 ± 67.4 | 217.8 ± 58.7 |
| Week 26: Before breakfast | 171.7 ± 39.6 | 178.2 ± 44.4 |
| Week 26: 90 minutes after start of breakfast | 247.2 ± 64.6 | 258.2 ± 63.7 |
| Week 26: Before lunch | 161.2 ± 51.0 | 177.0 ± 57.9 |
| Week 26: 90 minutes after start of lunch | 234.7 ± 63.3 | 255.3 ± 66.7 |
| Week 26: Before dinner | 162.3 ± 47.5 | 168.6 ± 57.5 |
| Week 26: 90 minutes after start of dinner | 233.3 ± 60.1 | 251.5 ± 64.9 |
| Week 26: At bedtime | 205.6 ± 58.6 | 220.5 ± 68.8 |
| Week 52: Before breakfast | 176.1 ± 43.2 | — |
| Week 52: 90 minutes after start of breakfast | 251.1 ± 69.1 | — |
| Week 52: Before lunch | 169.6 ± 59.7 | — |
| Week 52: 90 minutes after start of lunch | 243.3 ± 63.9 | — |
| Week 52: Before dinner | 164.3 ± 50.8 | — |
| Week 52: 90 minutes after start of dinner | 240.5 ± 65.8 | — |
| Week 52: At bedtime | 207.9 ± 66.7 | — |
Change from baseline (week 0) in mean of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Baseline (week 0) | 217.9 ± 46.7 | 217.7 ± 46.8 |
| Change from baseline: week 26 | -14.5 ± 39.0 | -0.6 ± 45.0 |
| Change from baseline: week 52 | -8.9 ± 43.7 | — |
Change from baseline (week 0) in mean of postprandial increments (from before meal to 90 minutes after for breakfast, lunch and dinner) of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 81.7 ± 38.7 | 81.6 ± 38.6 |
| Week 26: Change from baseline | -8.4 ± 43.8 | -1.5 ± 39.5 |
| Week 52: Change from baseline | -6.3 ± 44.4 | — |
Change from baseline (week 0) in FPG was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 172.5 ± 38.7 | 172.0 ± 38.3 |
| Week 26: Change from baseline | -8.4 ± 36.7 | 1.0 ± 33.7 |
| Week 52: Change from baseline | -1.2 ± 39.0 | — |
Change from baseline (week 0) in waist circumference was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| Centimeter (cm) | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 93.68 ± 11.75 | 93.82 ± 11.50 |
| Week 26: Change from baseline | -0.44 ± 3.04 | -0.73 ± 3.03 |
| Week 52: Change from baseline | -1.07 ± 3.64 | — |
Change from baseline (week 0) in body weight was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| Kilogram (kg) | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 74.67 ± 15.24 | 75.13 ± 16.46 |
| Week 26: Change from baseline | -0.77 ± 2.01 | -0.95 ± 2.19 |
| Week 52: Change from baseline | -1.05 ± 2.26 | — |
Change from baseline (week 0) in BMI was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| kg/m^2 | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 27.34 ± 4.80 | 27.20 ± 4.72 |
| Week 26: Change from baseline | -0.28 ± 0.72 | -0.33 ± 0.78 |
| Week 52: Change from baseline | -0.39 ± 0.82 | — |
Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mmHg | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: SBP, Baseline | 128.0 ± 13.1 | 128.8 ± 13.1 |
| Week 26: SBP, change from baseline | -1.7 ± 12.8 | 0.4 ± 12.2 |
| Week 52: SBP, change from baseline | -0.9 ± 12.5 | — |
| Week 0: DBP, Baseline | 79.6 ± 9.1 | 80.3 ± 9.8 |
| Week 26: DBP, change from baseline | -0.9 ± 8.7 | 0.1 ± 7.8 |
| Week 52: DBP, change from baseline | -0.6 ± 8.4 | — |
Fasting C-peptide was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| ng/mL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 1.946 ± 41.9 | 1.853 ± 40.8 |
| Week 52 | 1.906 ± 42.2 | — |
Fasting insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| pmol/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 77.00 ± 70.9 | 70.91 ± 65.3 |
| Week 52 | 77.31 ± 68.7 | — |
Fasting glucagon was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| pmol/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 22.5 ± 30.0 | 23.4 ± 26.8 |
| Week 52 | 23.4 ± 30.2 | — |
Proinsulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| pmol/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 15.638 ± 111.2 | 16.054 ± 101.8 |
| Week 52 | 16.217 ± 107.4 | — |
Proinsulin/insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| Percentage (%) of proinsulin/insulin | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 20.31 ± 70.7 | 22.64 ± 70.6 |
| Week 52 | 20.98 ± 72.5 | — |
HOMA-B was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-B is an index of beta-cell function and was calculated as: HOMA-B=\[(20 x fasting insulin in µU/mL)/(FPG in mmol/L-3.5)\].
| Percentage (%) of beta-cell function | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 42.06 ± 73.0 | 35.54 ± 72.9 |
| Week 52 | 40.03 ± 79.5 | — |
HOMA-IR was evaluated after 26 weeks and 52 weeks of treatment, respectively. HOMA-IR is an index of insulin resistance and was calculated as: HOMA-IR= fasting insulin (μU/mL) x FPG (mmol/L)/22.5.
| HOMA-IR score | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 4.388 ± 81.9 | 4.262 ± 73.5 |
| Week 52 | 4.567 ± 77.5 | — |
Total cholesterol was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 191.2 ± 17.6 | 194.5 ± 16.1 |
| Week 52 | 190.6 ± 16.3 | — |
LDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 103.4 ± 31.6 | 107.1 ± 27.8 |
| Week 52 | 104.5 ± 26.2 | — |
HDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 52.7 ± 25.6 | 52.9 ± 26.3 |
| Week 52 | 53.3 ± 24.7 | — |
VLDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 26.8 ± 56.7 | 27.8 ± 49.4 |
| Week 52 | 25.9 ± 55.2 | — |
Triglycerides were evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 135.4 ± 60.1 | 142.3 ± 54.9 |
| Week 52 | 130.4 ± 57.0 | — |
Free fatty acids were evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 26 | 12.56 ± 47.4 | 12.99 ± 43.9 |
| Week 52 | 12.19 ± 44.3 | — |
Treatment emergent adverse events (TEAEs) were evaluated during the 26-week and 52-week treatment period, respectively. TEAE for weeks 0-26: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 26 + 7 days). TEAE for weeks 0-52: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 52 + 7 days). Hence, the following shown 'Time Frame' should be read as 'Weeks 0-26 + 7 days and Weeks 0-52 + 7 days'.
| Events | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Weeks 0-26 | 365 | 266 |
| Weeks 0-52 | 588 | — |
Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the 26-week and 52-week treatment period, respectively. Severe or BG confirmed symptomatic hypoglycaemia (hypo):An episode that was severe according to the ADA classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypo. ADA definition of severe hypo:episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions. PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level. Treatment emergent: episode with onset date on or after randomisation (from week (wk) 0) and no later than 7 days after the last day on liraglutide (maximum till wk 26 and wk 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'wk 0-26+7 days and wk 0-52+7 days'.
| Episodes | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Weeks 0-26 | 0 | 0 |
| Weeks 0-52 | 0 | — |
Treatment emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the26-week and 52-week treatment period, respectively. Nocturnal hypoglycaemic episodes: Those occurring between 00:01 and 05:59 hours, both inclusive. Severe or BG confirmed symptomatic hypoglycaemia: episode that was severe according to the ADA classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Treatment emergent: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.
| Episodes | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Weeks 0-26 | 0 | 0 |
| Weeks 0-52 | 0 | — |
American Diabetes Association (ADA) classification of hypoglycaemia: 1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2. Documented symptomatic: PG level ≤3.9 mmol/L with symptoms. 3. Asymptomatic: PG level ≤3.9 mmol/L without symptoms. 4. Probable symptomatic: No measurement with symptoms. 5. Pseudo: PG level \>3.9 mmol/L with symptoms. Treatment emergent hypoglycaemic episode: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days). Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.
| Episodes | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Weeks 0-26: Severe hypoglycaemia | 0 | 0 |
| Weeks 0-26: Documented symptomatic hypoglycaemia | 0 | 0 |
| Weeks 0-26: Asymptomatic hypoglycaemia | 2 | 1 |
| Weeks 0-26: Probable symptomatic hypoglycaemia | 3 | 1 |
| Weeks 0-26: Pseudo-hypoglycaemia | 2 | 1 |
| Weeks 0-52: Severe hypoglycaemia | 0 | — |
| Weeks 0-52: Documented symptomatic hypoglycaemia | 0 | — |
| Weeks 0-52: Asymptomatic hypoglycaemia | 3 | — |
| Weeks 0-52: Probable symptomatic hypoglycaemia | 4 | — |
| Weeks 0-52: Pseudo-hypoglycaemia | 2 | — |
Change from baseline (week 0) in pulse was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| Beats/minute | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 80.2 ± 9.8 | 80.8 ± 10.4 |
| Week 26: Change from baseline | 0.8 ± 7.8 | 0.2 ± 7.9 |
| Week 52: Change from baseline | 0.2 ± 8.1 | — |
Reported results are physical examination outcomes at week (wk) 0, wk 26 and wk 52. Physical examination consisted of the following listed examinations and the outcome of each examination was evaluated as: 1) normal, 2) abnormal, not clinically significant (NCS) or 3) abnormal, clinically significant (CS). 1. Cardiovascular system 2. Central and peripheral nervous system (PNS) 3. Gastrointestinal (GI) system including mouth 4. General appearance 5. Head, ears, eyes, nose, throat, neck 6. Lymph node palpation 7. Musculoskeletal system 8. Respiratory system 9. Skin 10. Thyroid gland
| Participants | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Cardiovascular system: Wk 0: Normal | 229 | 230 |
| Cardiovascular system: Wk 0: Abnormal, NCS | 3 | 0 |
| Cardiovascular system: Wk 0: Abnormal, CS | 1 | 3 |
| Cardiovascular system: Wk 26: Normal | 230 | 229 |
| Cardiovascular system: Wk 26: Abnormal, NCS | 2 | 0 |
| Cardiovascular system: Week 26: Abnormal, CS | 1 | 4 |
| Cardiovascular system: Wk 52: Normal | 227 | — |
| Cardiovascular system: Wk 52: Abnormal, NCS | 4 | — |
| Cardiovascular system: Wk 52: Abnormal, CS | 2 | — |
| Central and PNS: Wk 0: Normal | 232 | 229 |
| Central and PNS: Wk 0: Abnormal, NCS | 0 | 1 |
| Central and PNS: Wk 0: Abnormal, CS | 1 | 3 |
| Central and PNS: Wk 26: Normal | 231 | 229 |
| Central and PNS: Wk 26: Abnormal, NCS | 0 | 1 |
| Central and PNS: Wk 26: Abnormal, CS | 2 | 3 |
| Central and PNS: Wk 52: Normal | 232 | — |
| Central and PNS: Wk 52: Abnormal, NCS | 0 | — |
| Central and PNS: Wk 52: Abnormal, CS | 1 | — |
| GI system including mouth: Wk 0: Normal | 227 | 226 |
| GI system including mouth: Wk 0: Abnormal, NCS | 0 | 4 |
| GI system including mouth: Wk 0: Abnormal, CS | 6 | 3 |
| GI system including mouth: Wk 26: Normal | 227 | 226 |
| GI system including mouth: Wk 26: Abnormal, NCS | 0 | 3 |
| GI system including mouth: Wk 26: Abnormal, CS | 6 | 4 |
| GI system including mouth: Wk 52: Normal | 226 | — |
| GI system including mouth: Wk 52: Abnormal, NCS | 2 | — |
| GI system including mouth: Wk 52: Abnormal, CS | 5 | — |
| General appearance: Wk 0: Normal | 229 | 232 |
| General appearance: Wk 0: Abnormal, NCS | 4 | 1 |
| General appearance: Wk 0: Abnormal, CS | 0 | 0 |
| General appearance: Wk 26: Normal | 229 | 233 |
| General appearance: Wk 26: Abnormal, NCS | 4 | 0 |
| General appearance: Wk 26: Abnormal, CS | 0 | 0 |
| General appearance: Wk 52: Normal | 229 | — |
| General appearance: Wk 52: Abnormal, NCS | 4 | — |
| General appearance: Wk 52: Abnormal, CS | 0 | — |
| Head,ears,eyes,nose,throat,neck: Wk0:Normal | 225 | 226 |
| Head,ears,eyes,nose,throat,neck: Wk0:Abnormal,NCS | 3 | 2 |
| Head,ears,eyes,nose,throat,neck: Wk0:Abnormal,CS | 5 | 5 |
| Head,ears,eyes,nose,throat,neck: Wk26:Normal | 225 | 228 |
| Head,ears,eyes,nose,throat,neck: Wk26:Abnormal,NCS | 4 | 1 |
| Head,ears,eyes,nose,throat,neck: Wk26:Abnormal,CS | 4 | 4 |
| Head,ears,eyes,nose,throat,neck: Wk52:Normal | 223 | — |
| Head,ears,eyes,nose,throat,neck: Wk52:Abnormal,NCS | 5 | — |
| Head,ears,eyes,nose,throat,neck: Wk52:Abnormal,CS | 5 | — |
| Lymph node palpation: Wk 0: Normal | 233 | 233 |
| Lymph node palpation: Wk 0: Abnormal, NCS | 0 | 0 |
| Lymph node palpation: Wk 0: Abnormal, CS | 0 | 0 |
| Lymph node palpation: Wk 26: Normal | 233 | 233 |
| Lymph node palpation: Wk 26: Abnormal, NCS | 0 | 0 |
| Lymph node palpation: Wk 26: Abnormal, CS | 0 | 0 |
| Lymph node palpation: Wk 52: Normal | 233 | — |
| Lymph node palpation: Wk 52: Abnormal, NCS | 0 | — |
| Lymph node palpation: Wk 52: Abnormal, CS | 0 | — |
| Musculoskeletal system: Wk 0: Normal | 226 | 231 |
| Musculoskeletal system: Wk 0: Abnormal, NCS | 4 | 0 |
| Musculoskeletal system: Wk 0: Abnormal, CS | 3 | 2 |
| Musculoskeletal system: Wk 26: Normal | 224 | 230 |
| Musculoskeletal system: Wk 26: Abnormal, NCS | 5 | 0 |
| Musculoskeletal system: Wk 26: Abnormal, CS | 4 | 3 |
| Musculoskeletal system: Wk 52: Normal | 224 | — |
| Musculoskeletal system: Wk 52: Abnormal, NCS | 5 | — |
| Musculoskeletal system: Wk 52: Abnormal, CS | 4 | — |
| Respiratory system: Wk 0: Normal | 233 | 232 |
| Respiratory system: Wk 0: Abnormal, NCS | 0 | 1 |
| Respiratory system: Wk 0: Abnormal, CS | 0 | 0 |
| Respiratory system: Wk 26: Normal | 232 | 232 |
| Respiratory system: Wk 26: Abnormal, NCS | 0 | 1 |
| Respiratory system: Wk 26: Abnormal, CS | 1 | 0 |
| Respiratory system: Wk 52: Normal | 232 | — |
| Respiratory system: Wk 52: Abnormal, NCS | 0 | — |
| Respiratory system: Wk 52: Abnormal, CS | 1 | — |
| Skin: Wk 0: Normal | 225 | 223 |
| Skin: Wk 0: Abnormal, NCS | 4 | 3 |
| Skin: Wk 0: Abnormal, CS | 4 | 7 |
| Skin: Wk 26: Normal | 218 | 222 |
| Skin: Wk 26: Abnormal, NCS | 4 | 4 |
| Skin: Wk 26: Abnormal, CS | 11 | 7 |
| Skin: Wk 52: Normal | 224 | — |
| Skin: Wk 52: Abnormal, NCS | 4 | — |
| Skin: Wk 52: Abnormal, CS | 5 | — |
| Thyroid gland: Wk 0: Normal | 232 | 232 |
| Thyroid gland: Wk 0: Abnormal, NCS | 0 | 0 |
| Thyroid gland: Wk 0: Abnormal, CS | 1 | 1 |
| Thyroid gland: Wk 26: Normal | 232 | 232 |
| Thyroid gland: Wk 26: Abnormal, NCS | 0 | 0 |
| Thyroid gland: Wk 26: Abnormal, CS | 1 | 1 |
| Thyroid gland: Wk 52: Normal | 232 | — |
| Thyroid gland: Wk 52: Abnormal, NCS | 0 | — |
| Thyroid gland: Wk 52: Abnormal, CS | 1 | — |
Reported results are eye examination (ophthalmoscopy) outcomes at week 0, week 26 and week 52. Ophthalmoscopy outcomes for both left and right eye were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.
| Participants | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Left eye - Normal | 183 | 176 |
| Week 0: Left eye - Abnormal, NCS | 15 | 13 |
| Week 0: Left eye - Abnormal, CS | 35 | 44 |
| Week 26: Left eye - Normal | 178 | 178 |
| Week 26: Left eye - Abnormal, NCS | 18 | 15 |
| Week 26: Left eye - Abnormal, CS | 37 | 40 |
| Week 52: Left eye - Normal | 181 | — |
| Week 52: Left eye - Abnormal, NCS | 16 | — |
| Week 52: Left eye - Abnormal, CS | 36 | — |
| Week 0: Right eye - Normal | 183 | 180 |
| Week 0: Right eye - Abnormal, NCS | 14 | 11 |
| Week 0: Right eye - Abnormal, CS | 36 | 42 |
| Week 26: Right eye - Normal | 176 | 180 |
| Week 26: Right eye - Abnormal, NCS | 19 | 14 |
| Week 26: Right eye - Abnormal, CS | 38 | 39 |
| Week 52: Right eye - Normal | 177 | — |
| Week 52: Right eye - Abnormal, NCS | 18 | — |
| Week 52: Right eye - Abnormal, CS | 38 | — |
Reported results are ECG outcomes at week 0, week 26 and week 52. ECG outcomes were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.
| Participants | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Normal | 202 | 196 |
| Week 0: Abnormal, NCS | 31 | 35 |
| Week 0: Abnormal, CS | 0 | 2 |
| Week 26: Normal | 205 | 204 |
| Week 26: Abnormal, NCS | 26 | 26 |
| Week 26: Abnormal, CS | 2 | 3 |
| Week 52: Normal | 203 | — |
| Week 52: Abnormal, NCS | 28 | — |
| Week 52: Abnormal, CS | 2 | — |
Change from baseline (week 0) in creatinine was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 0.802 ± 0.144 | 0.822 ± 0.164 |
| Week 26: Change from baseline | 0.018 ± 0.070 | 0.011 ± 0.080 |
| Week 52: Change from baseline | 0.025 ± 0.078 | — |
Change from baseline (week 0) in estimated glomerular filtration rate (eGFR) was evaluated after 26 weeks and 52 weeks of treatment, respectively. eGFR was evaluated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, mL/min/1.73m\^2.
| mL/min/1.73m^2 | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 78.6 ± 9.5 | 77.6 ± 10.7 |
| Week 26: Change from baseline | -1.5 ± 5.0 | -1.0 ± 5.8 |
| Week 52: Change from baseline | -2.3 ± 5.6 | — |
Change from baseline (week 0) in alanine aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| U/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 32.7 ± 19.5 | 34.2 ± 21.8 |
| Week 26: Change from baseline | -0.4 ± 12.0 | -2.2 ± 13.9 |
| Week 52: Change from baseline | -2.4 ± 11.9 | — |
Change from baseline (week 0) in aspartate aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| U/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 26.5 ± 12.8 | 26.9 ± 13.9 |
| Week 26: Change from baseline | 0.2 ± 9.9 | -1.0 ± 8.6 |
| Week 52: Change from baseline | -1.2 ± 8.9 | — |
Change from baseline (week 0) in alkaline phosphatase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| U/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 72.5 ± 20.6 | 74.1 ± 22.1 |
| Week 26: Change from baseline | 0.6 ± 9.8 | 2.0 ± 12.4 |
| Week 52: Change from baseline | 2.1 ± 11.1 | — |
Change from baseline (week 0) in sodium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mmol/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 140.2 ± 1.9 | 140.2 ± 1.9 |
| Week 26: Change from baseline | 0.1 ± 1.8 | 0.2 ± 2.0 |
| Week 52: Change from baseline | 0.3 ± 1.8 | — |
Change from baseline (week 0) in potassium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mmol/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 4.40 ± 0.34 | 4.38 ± 0.34 |
| Week 26: Change from baseline | -0.01 ± 0.32 | -0.02 ± 0.29 |
| Week 52: Change from baseline | 0.00 ± 0.31 | — |
Change from baseline (week 0) in albumin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| g/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 44.7 ± 2.5 | 45.1 ± 2.2 |
| Week 26: Change from baseline | -0.2 ± 2.1 | -0.2 ± 1.9 |
| Week 52: Change from baseline | -0.2 ± 2.2 | — |
Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 0.52 ± 0.29 | 0.53 ± 0.25 |
| Week 26: Change from baseline | 0.04 ± 0.25 | 0.04 ± 0.24 |
| Week 52: Change from baseline | 0.06 ± 0.23 | — |
Change from baseline (week 0) in urea was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 13.5 ± 3.2 | 14.0 ± 3.7 |
| Week 26: Change from baseline | 0.3 ± 3.0 | -0.0 ± 3.3 |
| Week 52: Change from baseline | 0.7 ± 2.8 | — |
Change from baseline (week 0) in creatine kinase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| U/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 117.3 ± 61.8 | 129.3 ± 100.3 |
| Week 26: Change from baseline | 5.2 ± 50.9 | -5.2 ± 96.3 |
| Week 52: Change from baseline | 7.5 ± 54.8 | — |
Change from baseline (week 0) in calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 9.66 ± 0.41 | 9.66 ± 0.37 |
| Week 26: Change from baseline | -0.01 ± 0.41 | 0.01 ± 0.39 |
| Week 52: Change from baseline | 0.01 ± 0.41 | — |
Change from baseline (week 0) in albumin corrected calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| mg/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 9.28 ± 0.35 | 9.26 ± 0.32 |
| Week 26: Change from baseline | 0.00 ± 0.37 | 0.02 ± 0.35 |
| Week 52: Change from baseline | 0.02 ± 0.36 | — |
Change from baseline (week 0) in amylase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| U/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 62.3 ± 23.1 | 61.1 ± 22.5 |
| Week 26: Change from baseline | -0.9 ± 12.5 | -2.3 ± 13.3 |
| Week 52: Change from baseline | -0.7 ± 12.1 | — |
Change from baseline (week 0) in lipase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| U/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 55.4 ± 26.1 | 57.3 ± 28.7 |
| Week 26: Change from baseline | -1.4 ± 23.4 | -3.3 ± 26.7 |
| Week 52: Change from baseline | -1.0 ± 22.0 | — |
Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| g/dL | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 14.65 ± 1.26 | 14.56 ± 1.35 |
| Week 26: Change from baseline | -0.00 ± 0.67 | 0.04 ± 0.57 |
| Week 52: Change from baseline | -0.00 ± 0.76 | — |
Change from baseline (week 0) in haematocrit was evaluated after 26 weeks and 52 weeks of treatment, respectively. Haematocrit is the ratio of the volume of red blood cells to the total volume of blood.
| % of red blood cell | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 44.86 ± 3.79 | 44.65 ± 4.03 |
| Week 26: Change from baseline | -0.22 ± 2.26 | -0.06 ± 1.90 |
| Week 52: Change from baseline | -0.49 ± 2.39 | — |
Change from baseline (week 0) in thrombocytes (platelets) was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| 10^9 cells/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 229.1 ± 47.4 | 231.0 ± 57.6 |
| Week 26: Change from baseline | 0.8 ± 27.4 | -1.5 ± 24.2 |
| Week 52: Change from baseline | 3.4 ± 24.9 | — |
Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| 10^12 cells/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 4.87 ± 0.41 | 4.89 ± 0.43 |
| Week 26: Change from baseline | -0.02 ± 0.24 | -0.00 ± 0.20 |
| Week 52: Change from baseline | -0.04 ± 0.25 | — |
Change from baseline (week 0) in leukocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| 10^9 cells/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 6.55 ± 1.71 | 6.53 ± 1.58 |
| Week 26: Change from baseline | 0.09 ± 1.15 | -0.08 ± 1.09 |
| Week 52: Change from baseline | 0.09 ± 1.44 | — |
Change from baseline (week 0) in eosinophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| 10^9 cells/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 0.182 ± 0.143 | 0.167 ± 0.158 |
| Week 26: Change from baseline | 0.001 ± 0.118 | -0.016 ± 0.104 |
| Week 52: Change from baseline | -0.008 ± 0.108 | — |
Change from baseline (week 0) in neutrophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| 10^9 cells/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 3.967 ± 1.337 | 3.975 ± 1.236 |
| Week 26: Change from baseline | 0.054 ± 1.029 | -0.088 ± 0.941 |
| Week 52: Change from baseline | 0.062 ± 1.239 | — |
Change from baseline (week 0) in basophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| 10^9 cells/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 0.024 ± 0.013 | 0.026 ± 0.013 |
| Week 26: Change from baseline | 0.004 ± 0.017 | 0.000 ± 0.016 |
| Week 52: Change from baseline | 0.000 ± 0.016 | — |
Change from baseline (week 0) in monocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| 10^9 cells/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 0.341 ± 0.133 | 0.326 ± 0.120 |
| Week 26: Change from baseline | 0.001 ± 0.101 | -0.000 ± 0.104 |
| Week 52: Change from baseline | 0.019 ± 0.153 | — |
Change from baseline (week 0) in lymphocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
| 10^9 cells/L | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Baseline | 2.034 ± 0.561 | 2.037 ± 0.583 |
| Week 26: Change from baseline | 0.032 ± 0.364 | 0.022 ± 0.389 |
| Week 52: Change from baseline | 0.014 ± 0.347 | — |
Reported results are number of subjects with low, normal or high calcitonin values at week 0, week 26 and week 52. Number of subjects analyzed = number of subjects contributed to the analysis for individual time point. Calcitonin values were categorised as low, normal or high.
| Participants | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Week 0: Low | 0 | 0 |
| Week 0: Normal | 229 | 229 |
| Week 0: High | 4 | 3 |
| Week 26: Low | 0 | 0 |
| Week 26: Normal | 228 | 231 |
| Week 26: High | 5 | 2 |
| Week 52: Low | 0 | — |
| Week 52: Normal | 230 | — |
| Week 52: High | 3 | — |
Collected over Liraglutide 1.8 mg treatment arm: Week 0 to week 52 (treatment period) + 7 days (follow-up period). Liraglutide 0.9 mg treatment arm: Week 0 to week 26 (treatment period) + 7 days (follow-up period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 1.8 mg | 0/233 (0%) | 8/233 (3.4%) | 99/233 (42.5%) |
| Liraglutide 0.9 mg | 0/233 (0%) | 3/233 (1.3%) | 65/233 (27.9%) |
| Event | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/233 | 0/233 |
| Calculus urinaryRenal and urinary disorders | 0/233 | 1/233 |
| Lacunar infarctionNervous system disorders | 0/233 | 1/233 |
| Pancreatitis acuteGastrointestinal disorders | 0/233 | 1/233 |
| CataractEye disorders | 1/233 | 0/233 |
| Large intestinal polypectomySurgical and medical procedures | 1/233 | 0/233 |
| Prostatic specific antigen increasedInvestigations | 1/233 | 0/233 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 1/233 | 0/233 |
| Squamous cell carcinoma of the vaginaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/233 | 0/233 |
| Tibia fractureInjury, poisoning and procedural complications | 1/233 | 0/233 |
| Event | Liraglutide 1.8 mg | Liraglutide 0.9 mg |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 66/233 | 44/233 |
| Diabetic retinopathyEye disorders | 23/233 | 17/233 |
| ConstipationGastrointestinal disorders | 17/233 | 5/233 |
| Lipase increasedInvestigations | 13/233 | 6/233 |
Full analysis set (FAS), which included all randomised subjects.
| Age, Continuous(Years) | Liraglutide 1.8 mg | Liraglutide 0.9 mg | Total |
|---|---|---|---|
| Mean | 55.07 ± 10.27 | 54.96 ± 10.61 | 55.01 ± 10.43 |
| Sex: Female, Male(Participants) | Liraglutide 1.8 mg | Liraglutide 0.9 mg | Total |
|---|---|---|---|
| Female | 77 | 68 | 145 |
| Male | 156 | 165 | 321 |
| Race (NIH/OMB)(Participants) | Liraglutide 1.8 mg | Liraglutide 0.9 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 233 | 233 | 466 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Glycosylated haemoglobin (HbA1c)(Percentage (%) of HbA1c) | Liraglutide 1.8 mg | Liraglutide 0.9 mg | Total |
|---|---|---|---|
| Mean | 8.14 ± 1.02 | 8.10 ± 0.87 | 8.12 ± 0.95 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · www.novonordisk-trials.com
Ran from Jul 2015 to primary completion in May 2017, 21 months.
Results were first posted in Jun 2018, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 21 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide